Seaport Therapeutics, Inc.
SPTX· Nasdaq
Released Aug 3, 2026, before the open
10-Q filed Aug 3, 2026, 34 days after period end · 0001193125-26-329537
| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Net Income | -$62.60M | -$15.08M |
| EPS Diluted | -$1.78 | -$6.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Seaport Therapeutics, Inc. · CIK 2042347 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 3, 2026 · 34 d after period end
+0.9% from the close of Jul 31, 2026 to the close of Aug 3, 2026, the first after the release.